Is There Evidence of Cognitive Decline from Cannabis In Dementia? 

As interest in medical cannabis continues to grow, questions remain about its impact on thinking and memory in people with dementia. While some hope cannabinoids might ease agitation or improve sleep, current research and UK clinical guidance raise concerns that cannabis-based medicines may worsen cognitive symptoms rather than improve them. 

According to NHS and NICE guidance, cannabis-based medical products, including THC, CBD, and synthetic cannabinoids such as dronabinol, are not recommended for dementia treatment due to a lack of proven benefit and potential cognitive risks (NHS Guidance; NICE NG97; NICE NG144). 

What The Research Shows 

Limited Evidence for Cognitive Benefit 

Most clinical trials on cannabis and dementia have focused on agitation, anxiety, or sleep, not cognition. Across these studies, there has been no consistent improvement in memory, attention, or executive function with cannabinoids. 

A 2023 double-blind crossover trial of older adults with dementia found no measurable change in cognitive scores between those given cannabinoids and those given placebo, despite minor improvements in agitation (PubMed Study). 

Similarly, systematic reviews from 2024 and 2025 concluded that cannabinoids do not enhance cognition in dementia and that data on long-term effects are too limited to rule out subtle declines (Meta-Analysis). 

Possible Cognitive Risks 

The potential for cannabis-based treatments to worsen cognitive decline remains a major concern. Cannabinoids interact with brain receptors involved in memory and attention, and chronic or high-dose exposure to THC may impair short-term memory, reaction time, and concentration. Although studies in dementia populations are small, researchers have observed increased confusion, drowsiness, and reduced alertness in some participants. The 2023 NICE surveillance review confirmed these safety concerns, noting insufficient evidence to rule out cognitive harm from cannabinoids in older or cognitively impaired adults (NICE 2023 Surveillance Review). 

Observations From General Cognitive Research 

Beyond dementia-specific trials, broader research has associated long-term THC exposure with memory impairment and executive dysfunction, particularly in older adults or those with pre-existing neurological conditions. The World Health Organization (WHO) notes that cannabis use may impair short-term memory and attention, and there is no evidence it slows or prevents cognitive decline in dementia (WHO: Cannabis and Cannabinoids). 

What Guidelines and Experts Say 

The NHS and NICE make clear distinctions between licensed medical use of cannabinoids and unproven or experimental applications. Licensed cannabis-based products can be prescribed by specialists for a few conditions such as severe epilepsy, chemotherapy-induced nausea, and spasticity in multiple sclerosis, but not dementia. 

According to NICE guidance NG97 and NG144, evidence for cannabis in dementia remains low quality and inconclusive, with no demonstrated improvement in cognition or function. NICE surveillance in 2023 reaffirmed this position, finding no new evidence to warrant changes to guidance. 

The Alzheimer’s Society UK reinforces these findings, explaining that cannabis and CBD products have not been shown to improve brain function in dementia. It warns that some cannabinoids may cause drowsiness or confusion, potentially worsening cognitive symptoms or increasing fall risk (Alzheimer’s Society). 

Evidence Quality and Limitations 

Researchers continue to explore whether cannabinoids might reduce agitation without impairing cognition. However, most available studies are small (fewer than 50 participants), short-term (under 12 weeks), and use varying formulations of THC and CBD. Such variability makes it difficult to compare outcomes or draw firm conclusions. Review authors stress the need for large-scale, randomised controlled trials to better understand whether any cognitive risks or benefits exist. 

The Clinical Bottom Line 

• Current research does not show cognitive improvement from cannabis-based treatments in dementia. 

• Some evidence suggests possible short-term confusion or drowsiness, especially with THC-rich formulations. 

• NICE and NHS guidance caution that cannabis is not recommended for dementia due to uncertain safety and no proven efficacy. 

• WHO notes potential for cognitive impairment with cannabis use, particularly in older adults. 

• Any use of cannabis in dementia should occur only within clinical research trials, not standard care. 

Educational Context: AlleviMed 

Educational organisations such as AlleviMed help clarify how medical cannabis eligibility is assessed in the UK. They provide information about the regulatory framework governing cannabis-based medicines, highlighting that only specific licensed indications, such as multiple sclerosis or epilepsy, qualify for prescription. Dementia remains outside these approved uses. AlleviMed’s educational materials also emphasise that cannabis use for unapproved conditions should only occur under specialist supervision within formal research studies, ensuring patient safety and regulatory compliance. 

Takeaway 

While interest in medical cannabis for dementia continues, no evidence supports cognitive improvement, and concerns remain that cannabinoids, especially THC, may worsen confusion or slow thinking. According to NHS, NICE, and WHO guidance, cannabis-based products should not be used for dementia outside approved trials. The safest approach to protecting cognitive health remains early diagnosis, evidence-based dementia care, and professional medical guidance.